Andrade PJD, Solares SME, Fernández CAJ, Viveros EJM, Rojas BL, Morales MJG, Mata MMP, Pérez OR, Pacheco GC, Calderón FF

Language: Spanish
References: 11
Page: 86-92
PDF size: 277.29 Kb.

ABSTRACT

Since prostate cancer is now more often detected in earlier stages, the urologist efforts must focus in offer treatments that could bring better results, long period of disease free survival and less morbidity. Radical prostatectomy has been first choice of treatment in localized prostate cancer. However, almost 40% will show early biochemical recurrence, requiring complementary treatments, therefore is necessary to analyze the real benefit of surgical radical procedures.
Material and methods. A cases review of radical prostatectomy for clinically localized prostate cancer, analyzing biochemical recurrence correlated with age, clinical stage, PSA, Gleason score and presence of extraprostatic disease.
Results. 156 patients with a follow-up of 70 months in average, in a 5 year follow-up show biochemical recurrence in 59% of cases, with a time to recurrence of 22 months, in the statistical analysis clinical stage (p= 0.01), biopsy Gleason score (p‹ 0.001), seminal vesicle invasion (p= 0.0006) and extraprostatic disease (p= 0.0001), shown to be statistically significant like risk factors for biochemical recurrence.
Conclusions. It’s necessary to reconsider indications of surgery, with the goal of avoiding recurrence we must select the cases with a low PSA and a Gleason score of less than 7, and consider the hystopathologic findings so we can offer adjuvant therapy when risk factors are detected.

REFERENCES

1. Solares ME, Soel J, Viveros JM, Rojas L, Pacheco C, Pérez R, Calderón F. Análisis de sobrevida en pacientes sometidos a prostatectomía radical, en población mexicana. Seguimiento a cinco años. Rev Mex Urol. 2004;64:54-66.

2. Crawford D. Prostate Cancer Annual Update 2005. Clinical care options. Postgraduate Institute for Medicine; pp 43-60.

3. Han M, Partin AW, Zhurak M, Epstein JI, Walsh PC. Biochemical recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169(2):517-3.

4. Nelson JB, Lepor H. Prostate cancer: radical prostatectomy. Urol Clin North Am. 2003;30(4):703-23.

5. Amling CL. Biochemical recurrence after localized treatment. Urol Clin North Am. 2006;33(2):147-59.

6. Jewett MA, Fleshner N, Klotz LH, Nam RK, Trachtenberg J. Radical prostatectomy as treatment for prostate cancer. CMJ. 2003;168(1):44-5.

7. Sokoloff MH, Rinker-Schaeffer CW, Chung LW, Brendler CB. Adjuntive Therapy for men with high risk localized and locally advanced prostate cancer: Targeting disseminated tumor cells. J Urol. 2004;172: 2539-44.

8. Kamat AM, Babaian K, Cheung MR, Naya Y, Huang S, Kuban D, Babaian RJ. Identification of factors predicting response to adjuvant therapy in patients with positive margins after radical prostatectomy. J Urol. 2003;170(5):1860-3.

9. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: Results of long-term follow-up. J Urol. 2004;172:1860-4.

10. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Carroll PR, Osswald MB, De Vere White R, Thompson IM, Crawford ED. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5- year followup, phase II southwest oncology group study 9109. J Urol. 2002;168(5):2016-9.

11. Hernandez DJ, Epstein JI, Trock BJ, Tsuzuki T, Carter HB, Walsh PC. Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostática extension in the region of the neurovascular bundle? J Urol. 2005;173(2):446-9.